HIK — Hikma Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- £3.11bn
- £4.17bn
- $3.35bn
Focus: US Health Secretary Kennedy speeds autism drug with GSK help
Brief: Hikma & Celltrion Strengthen Partnership To Expand Biosimilar Access In MENA
London's FTSE 100 closes at new record, powered by healthcare (updated)
London's FTSE 100 hits new record high as healthcare stocks surge
Brief: Hikma And Richter Receive FDA Approval For Denosumab Biosimilars Enobytm (Denosumab- Qbde) And Xtrenbotm (Denosumab- Qbde)
Hikma Pharmaceutical - Director/PDMR Shareholding
Hikma Pharmaceutical - Director/PDMR Shareholding
Brief: Hikma Pharmaceuticals USA Has Permanently Discontinued Oxycodone Hydrochloride Oral Solution
Hikma Pharmaceutical - Director/PDMR Shareholding
FTSE 100 hits record close as defence and financial stocks surge (updated)
UK Stocks-Factors to watch on August 14 (updated)
Hikma Pharmaceutical - Director/PDMR Shareholding
Europe Research Roundup: Euronext, Genuit Group, Melrose Industries
FTSE 100 rises as financial stocks gain; Ukraine talks in focus (updated)
FTSE 100 rises as healthcare, consumer gains eclipse fall in defence shares
Hikma Pharmaceutical - Director/PDMR Shareholding
Europe Research Roundup: Airbus, BBVA, Domino's Pizza
FTSE 100 slips after BoE rate decision, mixed earnings weigh on sentiment (updated)
Hikma outlook cut for unit's margins clouds confidence in overall forecasts (updated)